menu

Schedule Call

Cholangitis Diagnostics Market - Global Outlook and Forecast 2022-2030

GR - 500201 Category: Medical Devices

Number of pages: 100  |  Report Format: PDF  |  Published date: 01 November, 2022

Historical Years –   |  Base Year –   |  Forecasted Years –


Report Overview

Market Fundamentals

The changing lifestyles, increased healthcare awareness, and an increase in the geriatric population are expected to drive the growth of the global cholangitis diagnostics market. Moreover, the increased affordability of healthcare treatment and diagnosis, which has increased people's life expectancy is a key growth facilitator. People above 60 years suffer from different chronic diseases such as diabetes and cancer thus this population are more prone to cholangitis and requires therapies for cholangitis this are some of the factors which are propelling the growth of global cholangitis diagnostics market. 

The Global Cholangitis Diagnostics Market report presents in-depth assessment of this industry with specific focus on global and regional trends and future outlook. This report aims at providing global and regional segment analysis based on categories such as disease type, end user and geography. The report also proposes to include a study of the prevalent market drivers, restraints, and future opportunities on the global landscape. 

Market Ecosystem

Global Cholangitis Diagnostics Market, by Disease Type

  • Flexible Sigmoidoscopy 
  • Stool Diseases
  • Colonoscopy
  • CT Colonoscopy 
  • Others

Global Cholangitis Diagnostics Market, by End User

  • Hospitals and Specialty Clinics
  • Ambulatory Surgery Centers
  • Diagnostic Centers

Global Cholangitis Diagnostics Market, by Region

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Rest of the World
    • Latin America
    • Middle East & Africa

Key Market Trends

North America currently dominates the global Cholangitis Diagnostics Market due to factors such as rising geriatric population, awareness related to cholangitis. Moreover, the presence of prominent players in the region and the rise in the spending capacity on healthcare is playing a vital role in the regional growth. Asia Pacific has the fastest regional growth rate due to growing aged population, continuous investment form prominent market players and the rising spending expenditure. Countries in region such as India, China and Japan are presenting good growth opportunity.

Key Components of the Report 

  • In-depth review of the prevalent market trends
  • Annualized market size and forecast of every segment across 5 regions and 12 countries from 2020 to 2030
  • Market-specific analysis of the segments on the global level and further elaboration of trends in each region and country
  • Competitive landscape of the global market by key market players, based on market share or competitive positioning
  • Profiles of major market players based on business landscape, financial growth, and depth of product portfolio

Key Market Players 

Bayer AG, Taiho Pharmaceutical Co. Ltd., Gilead Sciences, RIEMSER Pharma GmbH, Zambon Company S.P.A., NGM Biopharmaceuticals, Intercept Pharmaceuticals Inc., HighTide Therapeutics Inc., Acorda Therapeutics Inc. SCOHIA PHARMA Inc. and other. 

Reasons to Buy this Report 

  • Detailed analysis of the impact of COVID-19 pandemic on the global Cholangitis Diagnostics Market
  • Develop your growth strategies through a review of the prevalent market trends, innovations, segment analysis, regional market landscape, and future opportunities
  • Identify the competitive landscape of the global market and understand the intensity of competition 
  • Identify the emerging market players and develop effective competitive strategies to overcome the competition
  • Track the revenue growth of the global, region and country-level markets and make effective expansion decisions
  • Our robust sources and research methodologies deliver accurate market sizing and forecast, which are further validated with authentic primary sources including CMOs from major market players and key opinion leaders

Frequently Asked Questions About This Report

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem 
    2. Timeline Under Consideration
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions       
  3. PREMIUM INSIGHTS
    1. Current Market Trend (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL CHOLANGITIS MARKET - ANALYSIS & FORECAST, BY DISEASE TYPE
    1. Acute Cholangitis
    2. Primary Sclerosing Cholangitis
    3. Secondary Sclerosing Cholangitis
    4. Recurrent Pyogenic
  6. GLOBAL CHOLANGITIS MARKET - ANALYSIS & FORECAST, BY END USER
    1. Clinical practice
    2. Academics and Research
    3. Other
  7. GLOBAL CHOLANGITIS MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Cholangitis Diagnostics Market
      1. North America Cholangitis Diagnostics Market, by Disease Type
      2. North America Cholangitis Diagnostics Market, by End User
      3. North America Cholangitis Diagnostics Market, by Country
        1. U.S.
          1. U.S. Cholangitis Diagnostics Market, by Disease Type
          2. U.S. Cholangitis Diagnostics Market, by End User
        2. Canada
          1. Canada Cholangitis Diagnostics Market, by Disease Type
          2. Canada Cholangitis Diagnostics Market, by End User
    2. Europe Cholangitis Diagnostics Market
      1. Europe Cholangitis Diagnostics Market, by Disease Type
      2. Europe Cholangitis Diagnostics Market, by End User
      3. Europe Cholangitis Diagnostics Market, by Country/Region
        1. Germany
          1. Germany Cholangitis Diagnostics Market, by Disease Type
          2. Germany Cholangitis Diagnostics Market, by End User
        2. U.K.
          1. U.K. Cholangitis Diagnostics Market, by Disease Type
          2. U.K. Cholangitis Diagnostics Market, by End User
        3. Spain
          1. Spain Cholangitis Diagnostics Market, by Disease Type
          2. Spain Cholangitis Diagnostics Market, by End User
        4. Italy 
          1. Italy Cholangitis Diagnostics Market, by Disease Type
          2. Italy Cholangitis Diagnostics Market, by End User
        5. France
          1. France Cholangitis Diagnostics Market, by Disease Type
          2. France Cholangitis Diagnostics Market, by End User
        6. Rest of Europe 
          1. Rest of Europe Cholangitis Diagnostics Market, by Disease Type
          2. Rest of Europe Cholangitis Diagnostics Market, by End User
    3. Asia Pacific Cholangitis Diagnostics Market
      1. Asia Pacific Cholangitis Diagnostics Market, by Disease Type
      2. Asia Pacific Cholangitis Diagnostics Market, by End User
      3. Asia Pacific Cholangitis Diagnostics Market, by Country/Region
        1. China
          1. China Cholangitis Diagnostics Market, by Disease Type
          2. China Cholangitis Diagnostics Market, by End User
        2. Japan
          1. Japan Cholangitis Diagnostics Market, by Disease Type
          2. Japan Cholangitis Diagnostics Market, by End User
        3. India
          1. India Cholangitis Diagnostics Market, by Disease Type
          2. India Cholangitis Diagnostics Market, by End User
        4. South Korea
          1. South Korea Cholangitis Diagnostics Market, by Disease Type
          2. South Korea Cholangitis Diagnostics Market, by End User
        5. Australia
          1. Australia Cholangitis Diagnostics Market, by Disease Type
          2. Australia Cholangitis Diagnostics Market, by End User
        6. Rest of Asia Pacific 
          1. Rest of Asia Pacific Cholangitis Diagnostics Market, by Disease Type
          2. Rest of Asia Pacific Cholangitis Diagnostics Market, by End User
    4. Rest of the World Cholangitis Diagnostics Market
      1. Rest of the World Cholangitis Diagnostics Market, By Region
        1. Rest of the World Cholangitis Diagnostics Market, by Disease Type
        2. Rest of the World Cholangitis Diagnostics Market, by End User
        3. Latin America
          1. Latin America Cholangitis Diagnostics Market, by Disease Type
          2. Rest of the World Cholangitis Diagnostics Market, by End User
        4. Middle East & Africa
          1. Middle East & Africa Cholangitis Diagnostics Market, by Disease Type
          2. Middle East & Africa Cholangitis Diagnostics Market, by End User
  8. COMPANY PROFILES        
    1. Bayer AG
      1. Business Snapshot 
      2. Products/Services Offered
      3. Financial Details*
      4. Strategic Developments
    2. Taiho Pharmaceutical Co. Ltd.
    3. Gilead Sciences
    4. RIEMSER Pharma GmbH
    5. Zambon Company S.P.A.
    6. NGM Biopharmaceuticals
    7. Intercept Pharmaceuticals Inc.
    8. HighTide Therapeutics Inc.
    9. Acorda Therapeutics Inc.
    10. SCOHIA PHARMA Inc.

        

*Insights on financial performance are subject to the availability of information in the public domain


Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.

Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.

GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.

sans

Snehal Deshmukh

Principle Consultant

Speak to analyst